Garda Raises ASRT Offer to $21.80: Merger Arb Setup With 63% Premium Over Unaffected Price

Event Summary

According to Assertio Holdings' official Business Wire press release dated May 4, 2026, Garda Therapeutics has raised its acquisition offer for Assertio Holdings, Inc. (Nasdaq: ASRT) to $21.80 per share all-cash — a 21.1% increase from the prior $18/share offer and a 63.1% premium to ASRT's unaffected price on March 20, 2026. The revised Amended and Restated Merger Agreement, signed May 1, 2026, eliminates the contingent value right (CVR) tied to SPRIX milestones that featured in the original April 8 deal, replacing it with a clean all-cash structure valuing the equity at $153.2 million.

The tender offer deadline was extended to May 4, 2026, with deal close expected in Q2 2026, subject to majority shareholder tender and customary regulatory conditions. Upon completion, ASRT will be delisted from Nasdaq. This deal is part of the broader pharma & fintech acquisition repricing trend reshaping small-cap healthcare valuations in 2026.

Leverage Impact Analysis

For traders using stock CFDs on CoinUnited.io — where up to 2000x leverage is available with zero trading fees — this merger arb setup has specific leverage dynamics worth understanding.

The core trade is a spread compression play: if ASRT shares trade at a discount to $21.80 (due to deal execution risk), a long CFD position profits as that spread closes toward tender close. Example: a trader opening a 50x long ASRT CFD at $20.50 (a hypothetical discount to the $21.80 offer price) sees a notional gain of approximately 6.3% on the position, amplified to ~315% at 50x leverage if the deal closes at $21.80 — but liquidation risk is severe if news of deal collapse pushes shares back toward pre-offer levels.

Key risk for leveraged longs: The original deal included a 20-day window-shop period, meaning a competing bid or deal termination remains possible. A deal break could see ASRT retrace sharply toward its unaffected March 20 price — representing a 38%+ downside from the current offer price. At 50x leverage, even a 2% adverse move erodes 100% of margin. Position sizing must reflect this binary outcome risk. Monitor open interest on CoinUnited.io for confirmation of positioning.

Cross-Market Impact

This is a small-cap, single-deal transaction ($153.2M equity value) with limited macro spillover. The M&A acquisition wave in pharma sends a modest positive signal to commercial-stage specialty pharma peers, but the deal size constrains any meaningful sector re-rating.

Healthcare sector ETFs (XLV, IBB) may see marginal positive read-through as the deal confirms acquirer appetite for commercial pharma assets. Broader indices (S&P 500, NASDAQ) are unaffected. Forex, commodities, and crypto markets have no direct exposure — this is a pure global acquisition consolidation wave story confined to the healthcare equity space. Traders interested in the wider sector M&A context can review the cross-sector acquisition repricing theme for related setups across pharma and adjacent verticals. For a deeper framework on trading these deals, see the M&A trading guide.

Trading Considerations

The key level is $21.80 — the hard ceiling set by the all-cash offer. Any ASRT trading below this price represents the market's implied probability of deal failure. Watch for: (1) formal tender commencement announcement, (2) regulatory clearance updates, and (3) any competing bid or termination notice within the window-shop period.

Risk factors include deal break (shares could fall 38%+ to unaffected levels), shareholder tender shortfall, and regulatory delay pushing close beyond Q2 2026. The clean all-cash structure (no CVR) reduces valuation ambiguity and typically compresses arb spreads faster than contingent deals.

Start Trading on CoinUnited.io

Create Your Free Account → — Trade crypto, stocks, forex, indices, and commodities with up to 2000x leverage and zero fees.